Dr. Ann Childress and Shane Schaffer, Chairman & CEO of Cingulate CING, have been lately visitors on Benzinga’s All Entry.
Cingulate is a biotechnology firm growing medicine for a variety of underserved situations. The corporate has developed a proprietary know-how referred to as Precision Timed Launch™ (PTR™). The know-how permits a single tablet to include a number of doses of a drug, relieving the tablet burden many individuals with continual situations endure.
Cingulate says it will likely be submitting a New Drug Software inside a yr.
Watch the complete interview right here:
Featured picture by Thought Catalog on Unsplash.
This submit incorporates sponsored content material. This content material is for informational functions solely and isn’t meant to be investing recommendation.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
